This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The chondroplasty market size has grown strongly in recent years. It will grow from $13.77 billion in 2024 to $14.68 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased sports-related injuries, patient preference for non-total joint replacement, postoperative care advances, healthcare provider training and expertise, increasing incidence of joint disorders.
The chondroplasty market size is expected to see strong growth in the next few years. It will grow to $18.43 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to regenerative medicine integration, focus on outpatient procedures, introduction of novel biomaterials, rise in musculoskeletal disorders, expansion of geriatric population. Major trends in the forecast period include technological integration in rehabilitation, arthroscopic techniques, cartilage repair and regeneration, technological innovations in surgical tools, integration of navigation systems.
The anticipated surge in joint-related disorders stands as a catalyst propelling the expansion of the chondroplasty market in the foreseeable future. These disorders encompass a range of health issues affecting joint functionality, often stemming from excessive joint use or abrupt injuries, such as accidents or sports-related incidents. Chondroplasty serves as a treatment for these joint-related disorders by addressing damaged cartilage within a joint. Recent data published by The Lancet in August 2023 highlighted a rise in the incidence of gout, an inflammatory arthritis impacting joints, in the UK. The diagnoses increased from 1.4 per 1,000 adults in March 2021 to 1.44 per 1,000 adults in March 2022. Furthermore, projections from the Centers for Disease Control and Prevention (CDC) in June 2023 estimate that by 2040, approximately 78.4 million (25.9%) US adults aged 18 years or older may receive doctor-diagnosed arthritis (BRFSS). Hence, the escalating prevalence of joint-related disorders is a driving force behind the chondroplasty market's growth trajectory.
The upswing in knee surgeries is poised to fuel the advancement of the chondroplasty market in the forthcoming period. Knee surgery denotes a surgical intervention targeting the knee joint to address a spectrum of conditions, injuries, or disorders impacting knee functionality. Chondroplasty, a surgical procedure focused on repairing and reshaping damaged cartilage within a joint, finds particular application in knee-related treatments. Notably, data from the National Library of Medicine revealed a substantial 18.3% increase in total hip and knee operations performed at over 1150 facilities in 2022 compared to 2020, totaling 2.4 million procedures. Moreover, projections from the same source in January 2023 indicate a projected surge of 139% in total knee arthroplasty (TKA) by 2040 and a striking 469% surge by 2060. As knee surgeries increase, the demand for chondroplasty is correspondingly boosted, fostering the growth dynamics of the chondroplasty market.
Leading companies in the chondroplasty market are advancing the development of autologous chondrocyte-based therapies to improve cartilage repair by leveraging patients' own cells, thereby minimizing immune rejection and encouraging natural regeneration. Autologous chondrocytes, which are cartilage cells harvested from a patient's body (typically from a non-weight-bearing area of the joint), provide a personalized approach to treatment. For example, in August 2024, Vericel Corporation, a U.S.-based biopharmaceutical company, gained FDA approval for its MACI Arthro (Matrix Autologous Chondrocyte Implantation), now commercially available. This innovation in knee cartilage defect treatment allows orthopedic surgeons to conduct the procedure through minimally invasive incisions using specialized instruments, offering a less invasive alternative to traditional methods. This approach is anticipated to improve patient recovery and reduce post-operative complications.
In July 2023, Avanos Medical Inc., a prominent US-based company specializing in pain management and chronic care solutions, successfully completed the acquisition of Diros Technology Inc. for a sum totaling $60 million. This strategic acquisition serves to bolster Avanos' standing as a frontrunner in the realm of radiofrequency (RF) technology, expanding its portfolio with a comprehensive range of cutting-edge pain treatment devices. Diros Technology Inc., based in Canada, specializes in crafting radiofrequency devices tailored to address joint disorders such as knee, cervical, and lumbar pain. This acquisition marks a significant step for Avanos, enriching its offerings and solidifying its position within the industry by integrating Diros' expertise and unique devices into its product line.
Major companies operating in the chondroplasty market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Osiris Therapeutics Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Medtronic Public Limited Company, Stryker Corporation, Teva Pharmaceutical Industries Ltd., B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Smith & Nephew PLC, Sigma-Aldrich Corporation, Arthrex Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., CONMED Corporation, Promega Corporation, Organogenesis Holdings Inc., Bioventus LLC, RTI Surgical Holdings Inc., Vericel Corporation, Geistlich Pharma AG, Ocugen Inc., MEDIPOST Co. Ltd., GPC Medical Ltd., Sklar Surgical Instruments, Isto Biologics, Nebula Inc., NuOrtho Surgical Inc., Medical Devices Business Services Inc.
North America was the largest region in the chondroplasty market in 2024. The regions covered in the chondroplasty market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chondroplasty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chondroplasty market includes revenues earned by entities by providing services such as microfracture surgery, laser-assisted treatments, and autologous chondrocyte transplantation (ACT). The market value includes the value of related goods sold by the service provider or included within the service offering. The chondroplasty market also includes sales of radiofrequency ablation devices and autologous chondrocyte implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Chondroplasty is a surgical procedure designed to repair and reshape damaged cartilage within a joint, commonly performed to alleviate pain and improve joint function in cases of cartilage damage caused by conditions such as osteoarthritis or traumatic injuries.
The main types of chondroplasty include radiofrequency ablation chondroplasty, abrasion chondroplasty, patellar chondroplasty, meniscal repair, tissue removal, and others. Radiofrequency ablation chondroplasty targets minor imperfections in knee cartilage to minimize joint deterioration. Various anatomies, such as knee, shoulder, hip, and others, are addressed using tools such as shavers, radiofrequency devices, and arthroscopes. Chondroplasty procedures are performed in settings such as hospitals, orthopedic clinics, academic research institutions, and others.
The chondroplasty market research report is one of a series of new reports that provides chondroplasty market statistics, including chondroplasty industry global market size, regional shares, competitors with a chondroplasty market share, detailed chondroplasty market segments, market trends and opportunities, and any further data you may need to thrive in the chondroplasty industry. This chondroplasty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The chondroplasty market size has grown strongly in recent years. It will grow from $13.77 billion in 2024 to $14.68 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to increased sports-related injuries, patient preference for non-total joint replacement, postoperative care advances, healthcare provider training and expertise, increasing incidence of joint disorders.
The chondroplasty market size is expected to see strong growth in the next few years. It will grow to $18.43 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to regenerative medicine integration, focus on outpatient procedures, introduction of novel biomaterials, rise in musculoskeletal disorders, expansion of geriatric population. Major trends in the forecast period include technological integration in rehabilitation, arthroscopic techniques, cartilage repair and regeneration, technological innovations in surgical tools, integration of navigation systems.
The anticipated surge in joint-related disorders stands as a catalyst propelling the expansion of the chondroplasty market in the foreseeable future. These disorders encompass a range of health issues affecting joint functionality, often stemming from excessive joint use or abrupt injuries, such as accidents or sports-related incidents. Chondroplasty serves as a treatment for these joint-related disorders by addressing damaged cartilage within a joint. Recent data published by The Lancet in August 2023 highlighted a rise in the incidence of gout, an inflammatory arthritis impacting joints, in the UK. The diagnoses increased from 1.4 per 1,000 adults in March 2021 to 1.44 per 1,000 adults in March 2022. Furthermore, projections from the Centers for Disease Control and Prevention (CDC) in June 2023 estimate that by 2040, approximately 78.4 million (25.9%) US adults aged 18 years or older may receive doctor-diagnosed arthritis (BRFSS). Hence, the escalating prevalence of joint-related disorders is a driving force behind the chondroplasty market's growth trajectory.
The upswing in knee surgeries is poised to fuel the advancement of the chondroplasty market in the forthcoming period. Knee surgery denotes a surgical intervention targeting the knee joint to address a spectrum of conditions, injuries, or disorders impacting knee functionality. Chondroplasty, a surgical procedure focused on repairing and reshaping damaged cartilage within a joint, finds particular application in knee-related treatments. Notably, data from the National Library of Medicine revealed a substantial 18.3% increase in total hip and knee operations performed at over 1150 facilities in 2022 compared to 2020, totaling 2.4 million procedures. Moreover, projections from the same source in January 2023 indicate a projected surge of 139% in total knee arthroplasty (TKA) by 2040 and a striking 469% surge by 2060. As knee surgeries increase, the demand for chondroplasty is correspondingly boosted, fostering the growth dynamics of the chondroplasty market.
Leading companies in the chondroplasty market are advancing the development of autologous chondrocyte-based therapies to improve cartilage repair by leveraging patients' own cells, thereby minimizing immune rejection and encouraging natural regeneration. Autologous chondrocytes, which are cartilage cells harvested from a patient's body (typically from a non-weight-bearing area of the joint), provide a personalized approach to treatment. For example, in August 2024, Vericel Corporation, a U.S.-based biopharmaceutical company, gained FDA approval for its MACI Arthro (Matrix Autologous Chondrocyte Implantation), now commercially available. This innovation in knee cartilage defect treatment allows orthopedic surgeons to conduct the procedure through minimally invasive incisions using specialized instruments, offering a less invasive alternative to traditional methods. This approach is anticipated to improve patient recovery and reduce post-operative complications.
In July 2023, Avanos Medical Inc., a prominent US-based company specializing in pain management and chronic care solutions, successfully completed the acquisition of Diros Technology Inc. for a sum totaling $60 million. This strategic acquisition serves to bolster Avanos' standing as a frontrunner in the realm of radiofrequency (RF) technology, expanding its portfolio with a comprehensive range of cutting-edge pain treatment devices. Diros Technology Inc., based in Canada, specializes in crafting radiofrequency devices tailored to address joint disorders such as knee, cervical, and lumbar pain. This acquisition marks a significant step for Avanos, enriching its offerings and solidifying its position within the industry by integrating Diros' expertise and unique devices into its product line.
Major companies operating in the chondroplasty market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Osiris Therapeutics Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Medtronic Public Limited Company, Stryker Corporation, Teva Pharmaceutical Industries Ltd., B. Braun Melsungen AG, Zimmer Biomet Holdings Inc., Smith & Nephew PLC, Sigma-Aldrich Corporation, Arthrex Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., CONMED Corporation, Promega Corporation, Organogenesis Holdings Inc., Bioventus LLC, RTI Surgical Holdings Inc., Vericel Corporation, Geistlich Pharma AG, Ocugen Inc., MEDIPOST Co. Ltd., GPC Medical Ltd., Sklar Surgical Instruments, Isto Biologics, Nebula Inc., NuOrtho Surgical Inc., Medical Devices Business Services Inc.
North America was the largest region in the chondroplasty market in 2024. The regions covered in the chondroplasty market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the chondroplasty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The chondroplasty market includes revenues earned by entities by providing services such as microfracture surgery, laser-assisted treatments, and autologous chondrocyte transplantation (ACT). The market value includes the value of related goods sold by the service provider or included within the service offering. The chondroplasty market also includes sales of radiofrequency ablation devices and autologous chondrocyte implants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Chondroplasty is a surgical procedure designed to repair and reshape damaged cartilage within a joint, commonly performed to alleviate pain and improve joint function in cases of cartilage damage caused by conditions such as osteoarthritis or traumatic injuries.
The main types of chondroplasty include radiofrequency ablation chondroplasty, abrasion chondroplasty, patellar chondroplasty, meniscal repair, tissue removal, and others. Radiofrequency ablation chondroplasty targets minor imperfections in knee cartilage to minimize joint deterioration. Various anatomies, such as knee, shoulder, hip, and others, are addressed using tools such as shavers, radiofrequency devices, and arthroscopes. Chondroplasty procedures are performed in settings such as hospitals, orthopedic clinics, academic research institutions, and others.
The chondroplasty market research report is one of a series of new reports that provides chondroplasty market statistics, including chondroplasty industry global market size, regional shares, competitors with a chondroplasty market share, detailed chondroplasty market segments, market trends and opportunities, and any further data you may need to thrive in the chondroplasty industry. This chondroplasty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chondroplasty Market Characteristics3. Chondroplasty Market Trends and Strategies4. Chondroplasty Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, Covid and Recovery on the Market32. Global Chondroplasty Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Chondroplasty Market34. Recent Developments in the Chondroplasty Market
5. Global Chondroplasty Growth Analysis and Strategic Analysis Framework
6. Chondroplasty Market Segmentation
7. Chondroplasty Market Regional and Country Analysis
8. Asia-Pacific Chondroplasty Market
9. China Chondroplasty Market
10. India Chondroplasty Market
11. Japan Chondroplasty Market
12. Australia Chondroplasty Market
13. Indonesia Chondroplasty Market
14. South Korea Chondroplasty Market
15. Western Europe Chondroplasty Market
16. UK Chondroplasty Market
17. Germany Chondroplasty Market
18. France Chondroplasty Market
19. Italy Chondroplasty Market
20. Spain Chondroplasty Market
21. Eastern Europe Chondroplasty Market
22. Russia Chondroplasty Market
23. North America Chondroplasty Market
24. USA Chondroplasty Market
25. Canada Chondroplasty Market
26. South America Chondroplasty Market
27. Brazil Chondroplasty Market
28. Middle East Chondroplasty Market
29. Africa Chondroplasty Market
30. Chondroplasty Market Competitive Landscape and Company Profiles
31. Chondroplasty Market Other Major and Innovative Companies
35. Chondroplasty Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Chondroplasty Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chondroplasty market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chondroplasty? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chondroplasty market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Radiofrequency Ablation Chondroplasty; Abrasion Chondroplasty; Atellar Chondroplasty; Meniscal Repair; Tissue Removal; Other Types2) By Anatomy: Knee; Shoulder; Hip; Other Anatomies
3) By Equipment: Shavers; Radiofrequency Devices; Arthroscope; Other Equipments
4) By End Use: Hospitals; Orthopedic Clinics; Academic Research; Other End Uses
Subsegments:
1) By Radiofrequency Ablation Chondroplasty: High-Frequency Ablation; Low-Frequency Ablation2) By Abrasion Chondroplasty: Mechanical Abrasion; Arthroscopic Abrasion
3) By Patellar Chondroplasty: Open Patellar Chondroplasty; Arthroscopic Patellar Chondroplasty
4) By Meniscal Repair: Suturing Techniques; Meniscal Allograft Transplantation
5) By Tissue Removal: Arthroscopic Debridement; Open Debridement
6) By Other Types: Microfracture Techniques; Osteochondral Autograft Transplantation
Key Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Osiris Therapeutics Inc.; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Chondroplasty market report include:- Johnson & Johnson
- F. Hoffmann-La Roche Ltd.
- Osiris Therapeutics Inc.
- Thermo Fisher Scientific Inc.
- Takeda Pharmaceutical Company Limited
- Medtronic Public Limited Company
- Stryker Corporation
- Teva Pharmaceutical Industries Ltd.
- B. Braun Melsungen AG
- Zimmer Biomet Holdings Inc.
- Smith & Nephew plc
- Sigma-Aldrich Corporation
- Arthrex Inc.
- Bio-Rad Laboratories Inc
- QIAGEN N.V.
- CONMED Corporation
- Promega Corporation
- Organogenesis Holdings Inc.
- Bioventus LLC
- RTI Surgical Holdings Inc.
- Vericel Corporation
- Geistlich Pharma AG
- Ocugen Inc.
- MEDIPOST Co. Ltd.
- GPC Medical Ltd.
- Sklar Surgical Instruments
- Isto Biologics
- Nebula Inc.
- NuOrtho Surgical Inc.
- Medical Devices Business Services Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 14.68 Billion |
| Forecasted Market Value ( USD | $ 18.43 Billion |
| Compound Annual Growth Rate | 5.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
